INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma

被引：0
|
作者：
Weber, Jeffrey S.
Luke, Jason J.
Carlino, Matteo S.
Khattak, Muhammad Adnan
Meehan, Robert S.
Brown, Michelle
Zhang, Jinchun
Krepler, Clemens
Duic, J. Paul
Long, Georgina V.
机构：
[1] NYU Langone Med Ctr, New York, NY USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Sydney, Sydney Med Sch, Fac Med & Hlth Sci, Camperdown, NSW, Australia
[4] Melanoma Inst Australia, Sydney, NSW, Australia
[5] Westmead & Blacktown Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW, Australia
[6] One Clin Res, Perth, WA, Australia
[7] Edith Cowan Univ, Perth, WA, Australia
[8] Moderna Inc, Cambridge, MA USA
[9] Merck & Co Inc, Rahway, NJ USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9616
引用
收藏
页数：1
相关论文
共 40 条
  • [31] Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*
    Kennedy, Oliver John
    Glassee, Nina
    Kicinski, Michal
    Blank, Christian U.
    V. Long, Georgina
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Boers-Sonderen, Marye
    Giacomo, Anna Maria Di
    Eertwegh, Alfonsus J. M. van den
    Grob, Jean -Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Akkooi, Alexander C. J. van
    Gandini, Sara
    Buhrer, Emanuel
    Suciu, Stefan
    Robert, Caroline
    Eggermont, Alexander M. M.
    Mandala, Mario
    Lorigan, Paul
    Valpione, Sara
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [32] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
    Eggermont, Alexander M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Rivas, Veronica
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Janssen, Sven
    van Akkooi, Alexander
    Suciu, Stefan
    Robert, Caroline
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
    Eggermont, A. M. M.
    Kicinski, M.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A. M.
    Meshcheryakov, A.
    Khattak, A.
    Carlino, M. S.
    Sandhu, S. K.
    Sarda, S. S. Puig
    Ascierto, P. A.
    Lorigan, P.
    Grebennik, D.
    Ibrahim, N.
    Marreaud, S. I.
    Suciu, S.
    Robert, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S912 - S913
  • [34] Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
    Eggermont, A. M. M.
    Kicinski, M.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A. M.
    Meshcheryakov, A.
    Khattak, M. A.
    Carlino, M. S.
    Sandhu, S. K.
    Sarda, S. Puig
    Ascierto, P. A.
    Lorigan, P.
    Grebennik, D.
    Krepler, C.
    Marreaud, S. I.
    Suciu, S.
    Robert, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S725 - S726
  • [35] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Tryfonidis, K.
    Karantza, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [36] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
    Bottomley, A.
    Kicinski, M.
    Long, G. V.
    Mandala, M.
    Atkinson, V. G.
    Blank, C. U.
    Haydon, A. M.
    Dalle, S.
    Khattak, A.
    Carlino, M. S.
    Meshcheryakov, A.
    Sandhu, S. K.
    Puig Sarda, S. S.
    Coens, C.
    Suciu, S.
    Grebennik, D.
    Krepler, C.
    Lorigan, P.
    Robert, C.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1410 - S1411
  • [37] AN ASSESSMENT OF DTIC VERSUS LEVAMISOLE OR PLACEBO IN THE TREATMENT OF HIGH-RISK STAGE-I PATIENTS AFTER SURGICAL REMOVAL OF A PRIMARY MELANOMA OF THE SKIN - A PHASE-III ADJUVANT STUDY - EORTC PROTOCOL 18761
    LEJEUNE, FJ
    MACHER, E
    KLEEBERG, U
    RUMKE, P
    PRADE, M
    THOMAS, D
    SUCIU, S
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 : S81 - S90
  • [38] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
    Eggermont, A. M. M.
    Blank, C. U.
    Mandala', M.
    Long, G. V.
    Atkinson, V.
    Dalle, S.
    Haydon, A. M.
    Meshcheryakov, A.
    Khattak, A.
    Carlino, M.
    Sandhu, S.
    Sarda, S. Puig
    Ascierto, P. A.
    van Akkooi, A. C. J.
    Krepler, C.
    Ibrahim, N.
    Marreaud, S. I.
    Kicinski, M.
    Suciu, S.
    Robert, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1175 - S1175
  • [39] Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial
    Coens, C.
    Bottomley, A.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A.
    Lichinitser, M.
    Khattak, A.
    Carlino, M. S.
    Sandhu, S. K.
    Larkin, J.
    Puig Sarda, S.
    Ascierto, P. A.
    Schadendorf, D.
    Ibrahim, N.
    Suciu, S.
    Robert, C.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2018, 29 : 456 - 456
  • [40] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
    Eggermont, Alexander M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew Mark
    Meshcheryakov, Andrey
    Khattak, Muhammad
    Carlino, Matteo S.
    Sandhu, Shahneen Kaur
    Puig, Susana
    Ascierto, Paolo Antonio
    Christopher, Alexander
    Van Akkooi, Jonathan
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
1234